One of the likely causes could be the fact that anti-VEGF therapy induces disruption of tumour vessels and consequent hypoxia, which results in dramatic changes in various signalling cascades in the tumour microenvironment, as seen in microarray analysis (Fig. 2a). This evidence concerns the gene VEGFA and neoplasm.